MYC and B-cell non-Hodgkin lymphoma: [11] DLBCLs with both an IGH-BCL2 and a MYC rearrangement, currently denoted “high-grade B-cell lymphoma with MYC and BCL2 rearrangements”, are associated with poor clinical outcomes [12].